NEW YORK – Genetic Technologies said on Tuesday that it has priced a public offering of 4 million American Depositary Shares (ADSs) at an effective purchase price of $2 per ADS.
Each ADS represents 600 of the Australian molecular diagnostic firm's ordinary shares. Gross proceeds of the offering, which is set to close on May 28, are expected to be roughly $8 million.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.